Sex-determining region Y-related high mobility group box (SOX)-2 is overexpressed in cervical squamous cell carcinoma and contributes cervical cancer cell migration and invasion in vitro.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: IOS Press Country of Publication: Netherlands NLM ID: 8409922 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0380 (Electronic) Linking ISSN: 10104283 NLM ISO Abbreviation: Tumour Biol Subsets: MEDLINE
    • Publication Information:
      Publication: 2021- : Amsterdam, The Netherlands : IOS Press
      Original Publication: Tokyo, Japan : Saikon Pub. Co., c1984-
    • Subject Terms:
      Cell Movement*; Biomarkers, Tumor/*metabolism ; Carcinoma, Squamous Cell/*pathology ; SOXB1 Transcription Factors/*metabolism ; Uterine Cervical Neoplasms/*pathology ; Uterine Cervical Dysplasia/*pathology; Apoptosis ; Biomarkers, Tumor/genetics ; Blotting, Western ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/metabolism ; Cell Proliferation ; Female ; Humans ; Immunoenzyme Techniques ; Middle Aged ; Neoplasm Grading ; Neoplasm Invasiveness ; Prognosis ; RNA, Messenger/genetics ; Real-Time Polymerase Chain Reaction ; Reverse Transcriptase Polymerase Chain Reaction ; SOXB1 Transcription Factors/genetics ; Tumor Cells, Cultured ; Uterine Cervical Neoplasms/genetics ; Uterine Cervical Neoplasms/metabolism ; Wound Healing ; Uterine Cervical Dysplasia/genetics ; Uterine Cervical Dysplasia/metabolism
    • Abstract:
      Sex-determining region Y-related high mobility group box 2 (SOX-2) is a key pluripotency-associated transcription factor and may be implicated in the pathogenesis of cervical squamous cell carcinoma (SCC). The aim of this study was to explore SOX-2 expression in cervical SCC tissues and to examine whether and how SOX-2 regulates the malignant behaviors of cervical SCC cells in vitro. We here found that SOX-2 expression in the examined cervical SCC tissues was higher than that in the normal cervical and cervical intraepithelial neoplasia (CIN) tissues. Higher protein level of SOX-2 (nuclear positive staining cells ≥50 %) was detected in 34.9 % (29 out of 83 cases) of cervical SCC patients. We also noted that 100 % of well-differentiated and 66.7 % of moderately differentiated cervical SCCs showed lower SOX-2 expression (nuclear positive staining cells <50 %), while 58.8 % of poorly differentiated tumors had higher SOX-2 expression (P < 0.05). Furthermore, the migratory and invasive capabilities of SiHa cervical cancer cells were enhanced when SOX-2 was upregulated whereas suppressed when SOX-2 was downregulated. Also, the phosphorylation levels of protein kinase B (Akt) and extracellular regulated protein kinases (ERK) 1/2 were increased in SOX-2-overexpressed cancer cells but decreased in SOX-2-depleted cells. Additionally, LY294002 (Akt pathway inhibitor) or U0126 (ERK pathway inhibitor) significantly suppressed SOX-2-overexpression-induced migration and invasion in SiHa cells. Our results indicate that differentially expressed SOX-2 is associated with tumor differentiation (P < 0.05) and that SOX-2 contributes to the migratory and invasive behaviors of cervical SCC in vitro.
    • References:
      Oncogene. 2012 Sep 6;31(36):4067-75. (PMID: 22179829)
      J Paediatr Child Health. 2014 Dec;50(12):959-65. (PMID: 24909919)
      Cancer Sci. 2013 Jul;104(7):810-6. (PMID: 23510069)
      Cell Signal. 2013 May;25(5):1264-71. (PMID: 23416461)
      Mol Cancer Ther. 2009 Mar;8(3):543-51. (PMID: 19258428)
      Carcinogenesis. 2014 Apr;35(4):942-50. (PMID: 24325912)
      Cell Prolif. 2012 Jun;45(3):207-16. (PMID: 22469032)
      Gynecol Oncol. 2014 Aug;134(2):419-25. (PMID: 24918866)
      Hum Pathol. 2010 Oct;41(10):1438-47. (PMID: 20709360)
      Biochem J. 2007 May 15;404(1):15-21. (PMID: 17302559)
      Clin Cancer Res. 2012 Mar 1;18(5):1464-71. (PMID: 22235101)
      Nucleic Acids Res. 2003 Jul 15;31(14):e73. (PMID: 12853650)
      PLoS One. 2012;7(8):e41335. (PMID: 22912670)
      Ann Surg Oncol. 2009 Dec;16(12 ):3488-98. (PMID: 19657699)
      Curr Cancer Drug Targets. 2013 Feb;13(2):205-20. (PMID: 23259831)
      OMICS. 2013 Oct;17(10):510-8. (PMID: 23895273)
      Int J Gynaecol Obstet. 2009 May;105(2):103-4. (PMID: 19367689)
      PLoS One. 2013 Apr 19;8(4):e61427. (PMID: 23620753)
      J BUON. 2014 Jan-Mar;19(1):203-6. (PMID: 24659665)
      BMC Cancer. 2011 Jan 28;11:42. (PMID: 21276239)
      Br J Cancer. 2011 Apr 26;104(9):1410-7. (PMID: 21468047)
      Cochrane Database Syst Rev. 2014 May 29;(5):CD010870. (PMID: 24874726)
      Discov Med. 2012 Aug;14(75):125-31. (PMID: 22935209)
      Viral Immunol. 2003;16(2):111-21. (PMID: 12828864)
      Oncogene. 2008 Sep 1;27(38):5110-4. (PMID: 18758479)
    • Contributed Indexing:
      Keywords: Cervical squamous cell carcinoma; Clinicopathologic features; Invasion; Migration; Sex-determining region Y-related high mobility group box 2
    • Accession Number:
      0 (Biomarkers, Tumor)
      0 (RNA, Messenger)
      0 (SOX2 protein, human)
      0 (SOXB1 Transcription Factors)
    • Publication Date:
      Date Created: 20150504 Date Completed: 20160128 Latest Revision: 20221207
    • Publication Date:
      20240829
    • Accession Number:
      10.1007/s13277-015-3450-y
    • Accession Number:
      25935536